Progress of Research on Novel Immune Checkpoints in Occurrence,Development and Immunotherapy of Gastric Cancer

VernacularTitle:新型免疫检查点在胃癌发生、发展以及免疫治疗中的研究进展
Author: Runbing ZHANG ^{1
,

2} ; Chun GAO ; Yang WU ; Tingting SHI ; Jie BAI ; Jun MA ; Xiaohui YU ; Jiucong ZHANG
Author Information

1. 中国人民解放军联勤保障部队第九四〇医院消化内科(730050)
2. 甘肃中医药大学第一临床医学院
Keywords: Stomach Neoplasms; Immune Checkpoints; Immunotherapy
From: Chinese Journal of Gastroenterology 2023;28(11):677-682
CountryChina
Language:Chinese
Abstract: Gastric cancer is one of the most common cancers in the world,and with the rise of immune-targeted therapy,it has provided new treatment options for many patients with advanced gastric cancer.However,not all cancer patients can benefit from monoclonal antibody therapy against programmed death-1 and its ligand and against cytotoxic T lymphocyte associated antigen-4.Therefore,the discovery of new immune checkpoints has become a future therapeutic trend.In this review,we summarized and analyzed the biological characteristics of V-domain Ig suppressor of T cell activation,B7 homolog 3 and lymphocyte-activation gene 3 of novel immune checkpoint T cell activation,as well as their effects on the occurrence and development of gastric cancer.At the same time,the effectiveness of corresponding immunosuppressants in preclinical and clinical trials was also evaluated,in order to provide a theoretical reference for the targeted therapy of gastric cancer.